Q1 rev $8.9M (+2%); net loss $5.1M; DrugSorb-ATR FDA submission delayed to late 2026/early 2027

Cytosorbents Corp

2026-Q1 EPS reported -$0.08 vs consensus -$0.06 ▼ miss (-42.6%)

Revenue $8.9M, +2% YoY; gross margin 69% vs 71% in Q1 2025.
Net loss $5.1M ($0.08/share) vs $1.5M ($0.02) in Q1 2025, driven by non-cash FX; adjusted net loss improved to $3.4M ($0.05).
Cash $6.4M vs $7.8M Dec 31; cash burn $1.1M (excl. $0.3M restructuring); targeting operating cash flow breakeven H2 2026.
DrugSorb-ATR for Brilinta: new De Novo submission delayed to late 2026/early 2027 after FDA requested additional mechanistic data.
Distributor orders delayed ~$500k in Middle East due to U.S.-Iran war; Germany direct sales slightly down but with smaller team.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytosorbents Corp reported first quarter ended March 31, 2026 results: revenue $8.9 million, net income $5.1 million or $0.08 per share, EPS $0.08 per share.

Period: first quarter ended March 31, 2026
Revenue: $8.9 million
Net income: $5.1 million or $0.08 per share
EPS: $0.08 per share
Result: reported results

Exact text from the filing

CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update PRINCETON, N .J ., May 13, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2026, recent business highlight s, and provides a regulatory update. First Quarter 2026 Financial Results • Revenue was $8.9 million, an increase of 2% over the prior year, from $8.7 million • Gross margin was 69% in the quarter compared to 71% in Q1 2025 • Operating loss was $3.0 million, compared to $3.9 million in Q1 2025 • Net loss was $5.1 million or $0.08 per share, compared to a net loss of $1.5 million or $0.02 per share in Q1 2025.

View on SEC.gov

Browse all earnings releases →

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0000929638-26-001834

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.